Actively Recruiting
Evaluating Nerandomilast Safety, Body Processing, and Effects in Children and Adolescents With Fibrosing Interstitial Lung Disease
Led by Boehringer Ingelheim · Updated on 2026-10-27
35
Participants Needed
47
Research Sites
102 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to study children and adolescents aged 2 to 17 years who have fibrosing interstitial lung disease ILD. The trial evaluates how the drug nerandomilast is tolerated, processed by the body, and whether it helps young patients with ILD. Nerandomilast has been approved in some countries for adults with a similar lung condition called idiopathic pulmonary fibrosis. The study is designed to better understand the effects and safety of nerandomilast in this younger population. Participants aged 6 to 17 years are randomly assigned to one of two groups for the first part of the study one group receives nerandomilast, and the other receives a placebo that looks like the medicine but contains no active drug. They take tablets twice daily for 6 months. After this, all participants in this age group receive nerandomilast for at least 2 years in the second part of the study. Younger participants aged 2 to 5 years start nerandomilast treatment immediately and take the tablets twice daily for at least two and a half years. Over the course of the study, which lasts between two and a half to five years depending on when participants join, individuals may have about 18 to 30 visits to the study site. During these visits, doctors collect blood samples to monitor health and how the body handles the medicine. Lung function, growth, and quality of life are also regularly assessed. For participants aged 6 to 17 years, results from the nerandomilast group are compared to those receiving placebo to evaluate treatment effects.
CONDITIONS
Brief Title
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here